ERISPharmaceuticals
Eris Lifesciences Ltd — Cash Flow Statement
₹1297.20
+2.05%
Eris Lifesciences Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 910.01 Cr | 356.85 Cr | -549.68 Cr | 257.23 Cr | — |
| Repayment Of Debt | -1.83K Cr | -159.40 Cr | -350.00 Cr | 0.00 | — |
| Issuance Of Debt | 1.44K Cr | 1.62K Cr | 1.17K Cr | 45.00 Cr | — |
| Issuance Of Capital Stock | 7.22 Cr | 4.54 Cr | 2.28 Cr | 7.20 Cr | — |
| Capital Expenditure | -155.00 Cr | -129.16 Cr | -841.42 Cr | -121.03 Cr | — |
| End Cash Position | 199.74 Cr | 94.25 Cr | 56.02 Cr | 50.87 Cr | — |
| Other Cash Adjustment Outside Changein Cash | 1.77 Cr | 26.96 Cr | 7.49 Cr | — | — |
| Beginning Cash Position | 94.25 Cr | 56.02 Cr | 50.87 Cr | 36.91 Cr | — |
| Changes In Cash | 103.72 Cr | 11.27 Cr | -2.34 Cr | 13.96 Cr | — |
| Financing Cash Flow | -881.32 Cr | 1.38K Cr | 688.02 Cr | -44.70 Cr | — |
| Net Other Financing Charges | -237.50 Cr | -10.27 Cr | — | 0.08 Cr | — |
| Interest Paid Cff | -145.06 Cr | -77.30 Cr | -23.43 Cr | -3.85 Cr | — |
| Cash Dividends Paid | -100.05 Cr | — | -99.91 Cr | -81.62 Cr | -74.68 Cr |
| Net Common Stock Issuance | 7.22 Cr | 4.54 Cr | 2.28 Cr | 7.20 Cr | — |
| Common Stock Issuance | 7.22 Cr | 4.54 Cr | 2.28 Cr | 7.20 Cr | — |
| Net Issuance Payments Of Debt | -397.21 Cr | 1.46K Cr | 817.80 Cr | 45.00 Cr | — |
| Net Long Term Debt Issuance | -397.21 Cr | 1.46K Cr | 817.80 Cr | 45.00 Cr | — |
| Long Term Debt Payments | -1.83K Cr | -159.40 Cr | -350.00 Cr | 0.00 | — |
| Long Term Debt Issuance | 1.44K Cr | 1.62K Cr | 1.17K Cr | 45.00 Cr | — |
| Investing Cash Flow | -79.97 Cr | -1.85K Cr | -982.10 Cr | -319.61 Cr | — |
| Net Other Investing Changes | 3.88 Cr | -1.21K Cr | -0.52 Cr | -0.10 Cr | — |
| Interest Received Cfi | 4.43 Cr | 6.99 Cr | 4.08 Cr | 5.03 Cr | — |
| Net Investment Purchase And Sale | 1.29K Cr | -1.16K Cr | 490.44 Cr | -188.19 Cr | — |
| Sale Of Investment | 1.29K Cr | 48.41 Cr | 520.44 Cr | 79.59 Cr | — |
| Net Business Purchase And Sale | -1.22K Cr | -566.80 Cr | -655.49 Cr | 0.00 | — |
| Purchase Of Business | -1.22K Cr | -566.80 Cr | -655.49 Cr | 0.00 | — |
| Net PPE Purchase And Sale | -154.63 Cr | -129.16 Cr | -841.28 Cr | -120.28 Cr | — |
| Sale Of PPE | 0.37 Cr | 0.00 | 0.14 Cr | 0.76 Cr | — |
| Purchase Of PPE | -155.00 Cr | -129.16 Cr | -841.42 Cr | -121.03 Cr | — |
| Operating Cash Flow | 1.07K Cr | 486.01 Cr | 291.74 Cr | 378.26 Cr | — |
| Taxes Refund Paid | -97.88 Cr | -100.75 Cr | -77.21 Cr | -83.28 Cr | — |
| Change In Working Capital | 125.97 Cr | -98.74 Cr | -175.54 Cr | -29.90 Cr | — |
| Change In Other Current Liabilities | 17.77 Cr | -95.88 Cr | 2.12 Cr | 2.71 Cr | — |
| Change In Other Current Assets | 119.46 Cr | -16.22 Cr | -76.46 Cr | -14.69 Cr | — |
| Change In Payable | 67.94 Cr | 90.98 Cr | -10.50 Cr | 15.16 Cr | — |
| Change In Inventory | -94.36 Cr | -16.94 Cr | 4.74 Cr | -23.45 Cr | — |
| Change In Receivables | -9.11 Cr | -57.09 Cr | -117.14 Cr | -20.48 Cr | — |
| Other Non Cash Items | 225.60 Cr | 77.34 Cr | 22.59 Cr | -4.30 Cr | — |
| Stock Based Compensation | 9.13 Cr | 0.75 Cr | 3.12 Cr | 1.35 Cr | — |
| Depreciation And Amortization | 315.46 Cr | 182.51 Cr | 117.09 Cr | 64.70 Cr | — |
| Amortization Cash Flow | 224.38 Cr | 126.97 Cr | 82.66 Cr | 44.93 Cr | — |
| Depreciation | 91.08 Cr | 55.54 Cr | 34.43 Cr | 19.78 Cr | — |
| Gain Loss On Investment Securities | -3.00 Cr | -9.38 Cr | -7.13 Cr | -16.61 Cr | — |
| Gain Loss On Sale Of PPE | 0.92 Cr | 2.14 Cr | 2.02 Cr | 4.25 Cr | — |
| Gain Loss On Sale Of Business | 0.00 | 0.80 Cr | 1.89 Cr | 0.00 | — |
| Net Income From Continuing Operations | 488.87 Cr | 431.34 Cr | 404.64 Cr | 442.20 Cr | — |
| Purchase Of Investment | — | -1.21K Cr | -30.00 Cr | -267.77 Cr | -373.39 Cr |
| Provisionand Write Offof Assets | — | 0.00 | 0.20 Cr | -0.15 Cr | 6.51 Cr |
| Repurchase Of Capital Stock | — | — | — | — | 0.00 |
| Common Stock Dividend Paid | — | — | — | — | -74.68 Cr |
| Common Stock Payments | — | — | — | — | 0.00 |
| Dividends Received Cfi | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Eris Lifesciences Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.